

Technology Appraisal Committee Meeting (Committee [A])

Minutes: Confirmed

Date and Time: 19th July 2016

Venue: Prospero House
24 High Street
SE1 7DA

Present:	1. Dr Jane Adam	Present for all notes
	2. Dr Jeremy Braybrooke	Present for all notes
	3. Dr Justin Daniels	Present for all notes
	4. Dr Rachel Hobson	Present for all notes
	5. Dr Anne McCune	Present for all notes
	6. Professor John McMurray	Present for all notes
	7. Dr Mohit Misra	Present for all notes
	8. Mrs Sarah Parry	Present for all notes
	9. Ms Pamela Rees	Present for all notes
	10. Dr Paul Robinson*LT	Present for all notes
	11. Ms Ellen Rule*LT	Present for all notes
	12. Dr Brian Shine	Present for all notes
	13. Mr David Thomson*LT	Present for all notes
	14. Dr John Watkins	Present for all notes
	15. Professor Olivia Wu	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Liv Gualda	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes

Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 14
Zoe Charles	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 14
Joanna Richardson	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 17 to 26
ERG - ScHARR Paul Tappenden	School of Health Related Research	Present for notes 1 to 14
Emma Simpson	School of Health Related Research	Present for notes 1 to 14
Daniel Pollard	School of Health Related Research	Present for notes 1 to 14
<u>Experts</u>		
Dr Simon Rule	Consultant Haematologist	Present for notes 1 to 14
Reta Brownlow	Patient expert	Present for notes 1 to 14
Mr Jonathan Pearce	Patient expert	Present for notes 1 to 14
Non-public observers:		
Mike Chambers	Committee member	
Heidi Livingstone	NICE, PPIP	Present for notes all notes
Aminata Thiam	NICE, CHTE TA	Present for notes all notes
Adam Storrow	NICE	Present for notes all notes
Joshua South	NICE, corporate office	Present for notes all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.
2. The Chair informed the Committee of the non-public observers at this meeting: Mike Chambers, Heidi Livingstone, Aminata Thiam, Adam Storrow and Joshua South
3. Apologies were received from Dr Graham Ash, Dr Andrew England, Mr Adrian Griffin, Mr Stephen Sharp and Dr Nerys Woolacott.

Notes from the last meeting

4. Minutes of the last meeting were agreed

Appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753]

Part 1 – Open session

5. The Chair welcomed the invited experts: Mrs Reta Brownlow, Mr Jonathan Pearce Dr Simon Rule, Dr Paul Tappenden, Emma Simpson and Daniel Pollard to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Janssen to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Jane Adam, Dr Justin Daniels, Dr Anne McCune Professor John McMurray, Dr Mohit Misra, Mrs Sarah Parry, Miss Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Dr Brian Shine Mr David Thomson, Dr John Watkins and Professor Olivia Wu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.
 - 7.2. Dr Jeremy Braybrooke declared a non-personal non specific financial interest as is co-investigator on clinical trials in breast cancer with studies sponsored by comparator companies in this appraisal.
 - 9.3.1 It was agreed that this declaration would not prevent Dr Jeremy Braybrooke from participating in this section of the meeting.

- 7.3. Dr Rachel Hobson declared a personal non-specific financial interest as she has sat on two advisory boards for Janssen in March/June 2015 in relation with diabetes.
 - 9.2.1 It was agreed that this declaration would not prevent Dr Rachel Hobson from participating in this section of the meeting.
 - 7.4. Mr Adrian Griffin declared a personal specific financial interest as Janssen is a Johnson and Johnson company. It was agreed that this declaration would prevent Mr Adrian Griffin from participating the meeting and he remained absent.
8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.
9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. Paul Tappenden, Emma Simpson, Daniel Pollard all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ibrutinib for treating relapsed or refractory mantle cell lymphoma
 - 9.2. Mrs Reta Brownlow declared a non-personal specific financial interest as Bloodwise has received an unrestricted grant from Janssen, but not specifically in relation with this appraisal.
 - 9.2.1. It was agreed that this declaration would not prevent Mrs Reta Brownlow from participating in this section of the meeting
 - 9.3. Mr Jonathan Pearce declared a non-personal specific financial interest as Lymphoma Association has previously received some financial support from Janssen (the manufacturer of the treatment under appraisal).
 - 9.3.1. It was agreed that this declaration would not prevent Mr Jonathan Pearce from participating in this section of the meeting
 - 9.4. Dr Simon Rule declared a personal non-specific financial interest as he has sat on advisory boards for Janssen
 - 9.4.1. It was agreed that this declaration would not prevent Dr Simon Rule from participating in this section of the meeting
10. The Chair introduced the lead team, Dr Paul Robinson, Ms Ellen Rule and Mr David Thomson who gave presentations on the clinical effectiveness and cost effectiveness of ibrutinib for treating relapsed or refractory mantle cell lymphoma.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of ibrutinib for treating relapsed or refractory mantle cell lymphoma
16. The Committee instructed the technical team to prepare the **Appraisal Consultation Document (ACD)** in line with their decisions.

Appraisal of Cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID815]

Part 1 – Open session

17. The Chair welcomed company representatives from Roche to the meeting.
18. The Chair asked all Committee members to declare any relevant interests
 - 18.1. Dr Jane Adam, Dr Justin Daniels, Dr Anne McCune Professor John McMurray, Dr Mohit Misra, Mrs Sarah Parry, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Dr Brian Shine Mr David Thomson, Dr John Watkins and Professor Olivia Wu declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma.
 - 18.2. Dr Jeremy Braybrooke declared a non-personal specific financial interest as he is a co-investigator on clinical trials in breast cancer with studies sponsored by comparator companies in this appraisal
 - 9.2.1 It was agreed that this declaration would not prevent Dr Jeremy Braybrooke from participating in this section of the meeting.
19. The Chair asked all NICE Staff to declare any relevant interests.
 - 19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma
20. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
22. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

23. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. Discussion on confidential information continued. This information was supplied by the company.
25. The Committee continued to discuss the clinical and cost effectiveness of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID815]
26. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

27. 10am, Tuesday 16th August 2016 at NICE London Office, Prince of Wales Suite 10 Spring Gardens SW1A 2BU